Share Prices & Company Research

Stockbroking

GlaxoSmithKline

Current Price 1667.20p Bid 1666.80p Ask 1667.60p Change -0.13%
Last Updated: 28/02/2024 22:38. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

Financial Highlights Year Ended 31/12/2023

Revenue
£30,328.00m
Operating Profit/Loss
£6,745.00m
Dividend yield (%)
2.90
Total dividend for year
n/ap
Dividend cover
3.69
P/E Ratio
9.40

Key Personnel

Ms Emma Walmsley
Chief Executive Officer
Ms Julie Brown
Chief Finance Officer
Mr Hal Barron
Chief Scientific Officer
Dr Jesse Goodman
Independent Non-Executive Director
Mr Elizabeth (Liz) McKee Anderson
Independent Non-Executive Director
Mr Harry (Hal) C. Dietz
Independent Non-Executive Director
Mr Urs Rohner
Independent Non-Executive Director
Mr Vishal Sikka
Independent Non-Executive Director
Mr Jonathan Symonds
Non-Executive Chairman
Dr Anne Beal
Non-Executive Director
Mr Charles Bancroft
Non-Executive Director

Stock Details

EPIC
GSKL
ISIN
GB0009252882
Shares in Issue
4,870.09m
Market cap
£81,194.14m

Analyst Views (5)

Strong Buy
 
0%
Buy
 
80.00%
Hold
 
20.00%
Sell
 
0%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect the views held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
1,667.20p
Bid Price
1,666.80p
Ask Price
1,667.60p
Volume
1,145,946
Change Today
-2.20p
% Change Today
-0.13%
Open
1,681.00p
Previous Close
1,667.20p
Intraday High
1,686.40p
Intraday Low
1,666.60p
52 Week High
1,686.40p
52 Week Low
1,313.60p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

News

GSK reports positive results from gonorrhoea treatment trial 26/02/2024 07:22:22 GSK's ViiV sees success in latest HIV treatment trial 21/02/2024 07:22:42 Berenberg hikes target price on GSK 15/02/2024 11:02:02 Citi ups recommendation on GSK to 'buy' 13/02/2024 09:45:12 GSK gets FDA fast track for chronic hepatitis B treatment 12/02/2024 07:21:23 GSK reports positive myeloma trial results, progresses vaccine applications 06/02/2024 07:23:47 GSK settles Zantac case in California without admitting liability 01/02/2024 09:11:53 GSK gets EU approval to sell blood cancer treatment Omijara 29/01/2024 07:07:38 Citi hikes target price for GSK but stays 'neutral' 26/01/2024 10:47:53 GSK raises £978m through Haleon share sale 17/01/2024 08:05:11 Zantac fallout unfairly weighing on GSK, says Shore Capital 15/01/2024 08:42:40 GSK's Nucala gets fresh approval in China 10/01/2024 07:22:23 GSK buys respiratory drug maker Aiolos for $1bn 09/01/2024 07:16:38 GSK buys rights to Hansoh Pharma antibody-drug conjugate 20/12/2023 13:29:49 GSK sees success in Jemperli endometrial cancer trial 18/12/2023 07:18:36 GSK seeks to extend RSV vaccine approval in Japan 12/12/2023 07:24:17 GSK endometrial cancer treatment gets Europe authorisation 11/12/2023 07:23:43 GSK receives 'positive' headline results from phase III trial 27/11/2023 08:02:39 GSK hikes guidance after strong third quarter 01/11/2023 07:27:49 GSK's Jemperli sees success in endometrial cancer trial 30/10/2023 07:06:45 GSK HIV injection regimen gets approval in China 26/10/2023 07:02:12 GSK hails success in US RSV vaccine trial 25/10/2023 07:27:55 GSK nears green light for Jemperli usage in Europe 16/10/2023 07:16:24 GSK settles California Zantac lawsuit 11/10/2023 11:51:40 GSK inks deal to promote shingles vaccine in China 09/10/2023 07:20:46

Income Statement

Year End Date
31 Dec 2023
31 Dec 2022
 
£ (M)
£ (M)
Continuing Operations
Revenue
30,328.00
29,324.00
Operating Profit/Loss
6,745.00
6,433.00
Net Interest
-677.00
-803.00
Pre-Tax Profit
6,064.00
5,628.00
Profit After Tax from continuing operations
5,308.00
4,921.00
Discontinued Operations
Profit After Tax
n/a
10,700.00
Profit/Loss for the Year
5,308.00
15,621.00
Attributable to:
Equity Holders of Parent Company
4,928.00
14,956.00
Minority Interests
380.00
665.00
Total Dividend Paid
n/ap
n/ap
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2023
31 Dec 2022
Basic
121.60p
110.80p
Diluted
119.90p
109.20p
Adjusted
155.10p
139.70p
Dividend per Share
n/ap
n/ap

Assets

Year End Date
31 Dec 2023
31 Dec 2022
 
£ (M)
£ (M)
Non-Current Assets
Property, Plant & Equipment
9,957.00
9,620.00
Intangible Assets
21,579.00
21,364.00
Investment Properties
n/a
n/a
Investments
1,192.00
1,541.00
Other Financial Assets
n/a
n/a
Other Non-Current Assets
7,633.00
6,852.00
Current Assets
Inventories
5,498.00
5,146.00
Trade & Other Receivables
7,385.00
7,053.00
Cash at Bank & In Hand
2,936.00
3,723.00
Current Asset Investments
2,246.00
4,154.00
Other Current Assets
579.00
693.00
Other Assets
n/a
n/a
Total Assets
59,005.00
60,146.00

Liabilities

Year End Date
31 Dec 2023
31 Dec 2022
 
£ (M)
£ (M)
Current Liabilities
Borrowings
2,813.00
3,952.00
Other Current Liabilities
18,255.00
18,858.00
Total Current Liabilities
21,068.00
22,810.00
Non-Current Liabilities
Borrowings
15,205.00
17,035.00
Provisions
806.00
821.00
Other Non-Current Liabilities
9,131.00
9,384.00
Total Non-Current Liabilities
25,142.00
27,240.00
Other Liabilities
n/a
n/a
Total Liabilities
46,210.00
50,050.00

Net Assets

Year End Date
31 Dec 2023
31 Dec 2022
 
£ (M)
£ (M)
Net Assets
12,795.00
10,096.00

Capital & Reserves

Year End Date
31 Dec 2023
31 Dec 2022
 
£ (M)
£ (M)
Share Capital
1,348.00
1,347.00
Share Premium Account
3,451.00
3,440.00
Other Reserves
1,309.00
1,448.00
Retained Earnings
7,239.00
4,363.00
Shareholders Funds
13,347.00
10,598.00
Minority Interests/Other Equity
-552.00
-502.00
Total Equity
12,795.00
10,096.00

Dividend History

Type
Ex-Dividend Date
Payment Date
Payment
Q4
22 Feb 2024
11 Apr 2024
16.00p
Q3
16 Nov 2023
11 Jan 2024
14.00p
Q2
17 Aug 2023
12 Oct 2023
14.00p
Q1
18 May 2023
13 Jul 2023
14.00p
Q4
23 Feb 2023
13 Apr 2023
13.75p
Q3
17 Nov 2022
12 Jan 2023
13.75p
Q2
18 Aug 2022
06 Oct 2022
16.25p
Q1
19 May 2022
01 Jul 2022
14.00p
Q4
24 Feb 2022
07 Apr 2022
23.00p
Q3
18 Nov 2021
13 Jan 2022
19.00p
Q2
19 Aug 2021
07 Oct 2021
19.00p
Q1
20 May 2021
08 Jul 2021
19.00p
Q4
18 Feb 2021
08 Apr 2021
23.00p
Q3
12 Nov 2020
14 Jan 2021
19.00p
Q2
13 Aug 2020
08 Oct 2020
19.00p
Q1
14 May 2020
09 Jul 2020
19.00p
Q4
20 Feb 2020
09 Apr 2020
23.00p
Q3
14 Nov 2019
09 Jan 2020
19.00p
Q2
08 Aug 2019
10 Oct 2019
19.00p
Q1
16 May 2019
11 Jul 2019
19.00p
Q4
21 Feb 2019
11 Apr 2019
23.00p
Q3
15 Nov 2018
10 Jan 2019
19.00p
Q2
09 Aug 2018
11 Oct 2018
19.00p
Q1
10 May 2018
12 Jul 2018
19.00p
Q4
22 Feb 2018
12 Apr 2018
23.00p
Q3
09 Nov 2017
11 Jan 2018
19.00p
Q2
10 Aug 2017
12 Oct 2017
19.00p
Q1
11 May 2017
13 Jul 2017
19.00p
Q4
23 Feb 2017
13 Apr 2017
23.00p
Q3
03 Nov 2016
12 Jan 2017
19.00p
Q2
11 Aug 2016
13 Oct 2016
19.00p
Q1
12 May 2016
14 Jul 2016
19.00p
Q4
18 Feb 2016
14 Apr 2016
23.00p
Q4
18 Feb 2016
14 Apr 2016
23.00p
Special
18 Feb 2016
14 Apr 2016
20.00p
Special
18 Feb 2016
14 Apr 2016
20.00p
Special
18 Feb 2016
14 Apr 2016
20.00p
Q3
12 Nov 2015
14 Jan 2016
19.00p
Q2
13 Aug 2015
01 Oct 2015
19.00p
Q1
14 May 2015
09 Jul 2015
19.00p

Dividend Metrics

Year End Date
31 Dec 2023
31 Dec 2022
Dividend growth
-4.55%
-45.00%
Dividend yield
2.90%
3.10%
Dividend cover
3.69
3.17


Cboe Global Markets® is a registered trade mark of Cboe Global Markets, Inc., a company incorporated in the United States of America with registered address at 400 South LaSalle Street, Chicago, IL 60605, USA. Cboe shall own any and all rights including without limitation Intellectual Property rights and any and all goodwill arising directly or indirectly out of the Recipient’s use of the “Cboe Global Markets®”, “Cboe®” and “Bats®”” trademarks. Neither Cboe nor its licensors accept any liability for any errors or omissions in the Cboe Europe Indices or underlying data. No further distribution of Cboe Europe data is permitted without Cboe’s express written consent.

The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.